IMUC:NYSE.MKT

ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company has concluded a Phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program, which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells.

Expert Comments:

Jason Kolbert, Maxim Group (5/13/15)
"ImmunoCellular Therapeutics Ltd. is completing a special protocol assessment (SPA) with the U.S. Food and Drug Administration for the ICT-107 Phase 3 trial in glioblastoma multiforme. . .plans for the clinical trial are being finalized, with an expected start in late Q3Q4/15. . .we see the SPA, the single trial and the interim looks as positives for the trial."

Jerry Isaacson, LifeSci Capital (4/2/15)
"Early Phase 1 results for ImmunoCellular Therapeutics Ltd.'s ICT-107 were promising and in an open-label Phase 1 trial, 16 patients with newly diagnosed glioblastoma (GBM) experienced a median progression-free survival of 16.9 months and a median overall survival of 38.4 months. . .the company intends to move forward with plans to initiate a Phase 3 trial based on the results of its Phase 2 trial. ImmunoCellular is also conducting a Phase 1 study with ICT-121 in patients with recurrent GBM."

Joseph Pantginis, ROTH Capital Partners (3/13/15)
"ImmunoCellular Therapeutics Ltd. announced FY/14 results posting EPS of $0.16. . .the company had $23.2M cash at the end of the year with current pro forma cash of $37.8M following an underwritten public offering in February 2015. We believe this year represents a turning point for ImmunoCelluar with the expected Phase 3 study start with ICT-107 in newly diagnosed glioblastoma patients, so we are reiterating our Buy rating."

Jason Kolbert, Maxim Group (3/10/15)
"Earlier this year, ImmunoCellular Therapeutics Ltd.'s ICT-107 was designated as an Advanced Therapy Medicinal Product by the EU Committee for Advanced Therapies, which should provide access in Phase 3 to valuable services and incentives offered by the EMEA should the company conduct the Phase 3 program in the EU. We believe that ICT-107 is a viable therapy for glioblastoma and that a pivotal trial in the U.S. is the next step."

Jason Kolbert, Maxim Group (11/19/14)
"ImmunoCellular Therapeutics Ltd. held a conference call following the Society for Neuro-Oncology meeting to discuss Phase 2 data presentations from the trial of ICM-107 in glioblastoma multiforme. . .the company plans to design a Phase 3 program that would allow for registration in both the US and Europe. . .we find the Phase 2 efficacy results to be very encouraging."

Joseph Pantginis, ROTH Capital Partners (11/14/14)
"ImmunoCellular Therapeutics Ltd. presented updated Phase 2 ICT-107 data. In the prospectively defined subgroup of patients likely to be the target group for Phase 3, 65% are still alive compared to 50% of control patients. We expect the company to quickly finalize its plans for a Phase 3 following positive FDA feedback. We reiterate our Buy rating."

More Expert Comments

Experts Commenting on This Company

Jerry Isaacson, Managing Director and Senior Analyst – LifeSci Advisors, LifeSci Capital
Jason Kolbert, Senior Analyst – Maxim Group
Joseph Pantginis, Senior Analyst – ROTH Capital Partners

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
 
Pivotal Phase 3 registration trial of lead cancer immunotherapeutic ICT-107 in brain cancer to begin in 2015
 
Proprietary cancer immunotherapy development pipeline advancing; represents multiple partnering opportunities
 
Stem-to-T-cell program advancing toward clinical trials; novel immuno-oncology approach
catalyst Calendar
ImmunoCellular Therapeutics Ltd. Content